surmount-1 trial tirzepatide weight loss nondiabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled SURMOUNT-1 Trial - Cardionerds Twitter

Eur Heart J 8:179186 McGowan BM, Bruun JM, Capehorn M et al (2024) Efficacy and safety of once-weekly semaglutide 24 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

This creates an audit trail that your healthcare provider can review during consultations

Tirzepatide cannot be legally compounded in a U.S

Photographs taken monthly under consistent lighting conditions provide visual evidence that the scale sometimes contradicts

Mast cell stabilizer (MCAS Connection): GLP-1 receptors are also found on mast cells, and recent studies have shown that GLP-1 RA drugs prevent overactive mast cell degranulation

This could trigger nausea more aggressively than an injection in the thigh, which is far removed from the digestive tract